Who are Syfovre™'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ranibizumab PRN, Ranibizumab and laser, Ketorolac + Ranibizumab, Ranibizumab and Aflibercept, Lucentis (Treat and extend), Ranibizumab plus Photodynamic therapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/syfovre.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Syfovre™ — Competitive Intelligence Brief

Syfovre™ (Syfovre™) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-VEGF aptamer. Area: Ophthalmology.

marketed Anti-VEGF aptamer VEGF-A Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Syfovre™ (Syfovre™) — Hoffmann-La Roche. Syfovre is an anti-VEGF aptamer that binds and inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth and leakage in the retina.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Syfovre™ TARGET	Syfovre™	Hoffmann-La Roche	marketed	Anti-VEGF aptamer	VEGF-A
ranibizumab PRN	ranibizumab PRN	Seoul National University Hospital	marketed	VEGF-A inhibitor monoclonal antibody fragment	VEGF-A (Vascular Endothelial Growth Factor A)
Ranibizumab and laser	Ranibizumab and laser	Fukushima Medical University	marketed	VEGF inhibitor (monoclonal antibody fragment) combined with laser photocoagulation	VEGF-A
Ketorolac + Ranibizumab	Ketorolac + Ranibizumab	Università degli Studi di Brescia	marketed	NSAID + anti-VEGF monoclonal antibody fragment	COX enzymes (ketorolac); VEGF-A (ranibizumab)
Ranibizumab and Aflibercept	Ranibizumab and Aflibercept	Instituto de Olhos de Goiania	marketed	Anti-VEGF agent	VEGF-A (vascular endothelial growth factor-A)
Lucentis (Treat and extend)	Lucentis (Treat and extend)	Retinal Consultants of Arizona	marketed	VEGF inhibitor (monoclonal antibody fragment)	VEGF-A
Ranibizumab plus Photodynamic therapy	Ranibizumab plus Photodynamic therapy	Illinois Retina Associates	marketed	Anti-VEGF monoclonal antibody fragment combined with photodynamic therapy	VEGF-A (ranibizumab component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-VEGF aptamer class)

Hoffmann-La Roche · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Syfovre™ — Competitive Intelligence Brief. https://druglandscape.com/ci/syfovre. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab